Sinovac obtains production license for H1N1 vaccine in China

China's State Food and Drug Administration (SFDA) has approved the registration application for PANFLU.1, Chinese biopharmaceutical firm Sinovac Biotoech's H1N1 vaccine, and has issued the company with a production license for this vaccine. Sinovac has the capacity to produce 5 million doses of vaccine before October 1, and 20 million to 30 million doses per year, said president the firm's president, Yin Weidong.

Another A/H1N1 flu vaccine, produced by Chinese pharmaceutical company Hualan Biological Engineering, is also hopeful to be given the country's second approval this week, reports the Shanghia Daily newspaper.